These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 19863619

  • 1. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    Luber AD, Condoluci DV, Slowinski PD, Andrews M, Olson K, Peloquin CA, Pappa KA, Pakes GE, COL104422 Study Team.
    HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
    [Abstract] [Full Text] [Related]

  • 2. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA, COL10053 Study Team.
    Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
    [Abstract] [Full Text] [Related]

  • 3. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    Kurowski M, Walli RK, Breske A, Kruse G, Stocker H, Banik N, Richter H, Mazur D.
    AIDS; 2007 Jun 19; 21(10):1368-70. PubMed ID: 17545717
    [Abstract] [Full Text] [Related]

  • 4. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
    Luber AD, Brower R, Kim D, Silverman R, Peloquin CA, Frank I.
    HIV Med; 2007 Oct 19; 8(7):457-64. PubMed ID: 17760738
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.
    Chittick GE, Zong J, Blum MR, Sorbel JJ, Begley JA, Adda N, Kearney BP.
    Antimicrob Agents Chemother; 2006 Apr 19; 50(4):1304-10. PubMed ID: 16569845
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
    Shelton MJ, Wire MB, Lou Y, Adamkiewicz B, Min SS.
    Antimicrob Agents Chemother; 2006 Mar 19; 50(3):928-34. PubMed ID: 16495253
    [Abstract] [Full Text] [Related]

  • 7. Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.
    Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, Castles MA, Robinson P.
    Basic Clin Pharmacol Toxicol; 2011 Mar 19; 108(3):163-70. PubMed ID: 20977679
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    McRae M, Clay PG, Anderson PL, Glaros AG.
    Pharmacotherapy; 2009 Aug 19; 29(8):937-42. PubMed ID: 19637947
    [Abstract] [Full Text] [Related]

  • 9. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
    Parks DA, Jennings HC, Taylor C, Pakes GE, Acosta EP.
    HIV Clin Trials; 2009 Aug 19; 10(3):160-7. PubMed ID: 19632955
    [Abstract] [Full Text] [Related]

  • 10. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug 19; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 11. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May 19; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 12. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
    Wire MB, Ballow CH, Borland J, Shelton MJ, Lou Y, Yuen G, Lin J, Lewis EW.
    Antimicrob Agents Chemother; 2007 Aug 19; 51(8):2982-4. PubMed ID: 17517848
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Cao YJ, Smith PF, Wire MB, Lou Y, Lancaster CT, Causon RC, Bigelow GE, Martinez E, Fuchs EJ, Radebaugh C, McCabe S, Hendrix CW.
    Pharmacotherapy; 2008 Jul 19; 28(7):863-74. PubMed ID: 18576901
    [Abstract] [Full Text] [Related]

  • 14. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    Seminari E, De Bona A, Gentilini G, Galli L, Schira G, Gianotti N, Uberti-Foppa C, Soldarini A, Dorigatti F, Lazzarin A, Castagna A.
    J Antimicrob Chemother; 2007 Oct 19; 60(4):831-6. PubMed ID: 17684056
    [Abstract] [Full Text] [Related]

  • 15. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Pham PA, Hendrix CW, Barditch-Crovo P, Parsons T, Khan W, Parish M, Radebaugh C, Carson KA, Pakes GE, Qaqish R, Flexner C.
    Antivir Ther; 2007 Oct 19; 12(6):963-9. PubMed ID: 17926651
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.
    Droste JA, Verweij-van Wissen CP, Kearney BP, Buffels R, Vanhorssen PJ, Hekster YA, Burger DM.
    Antimicrob Agents Chemother; 2005 Feb 19; 49(2):680-4. PubMed ID: 15673751
    [Abstract] [Full Text] [Related]

  • 17. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
    Wire MB, Baker KL, Jones LS, Shelton MJ, Lou Y, Thomas GJ, Berrey MM.
    Antimicrob Agents Chemother; 2006 Apr 19; 50(4):1578-80. PubMed ID: 16569890
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects.
    Ford SL, Chen YC, Lou Y, Borland J, Min SS, Yuen GJ, Shelton MJ.
    Antimicrob Agents Chemother; 2008 Feb 19; 52(2):534-8. PubMed ID: 18056271
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.